Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk
| Autor: | JoAnn Flaim, Wai Chin, Shariq Ali, Michael H. Davidson, William C. Cromwell, Gregory S. Thomas |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
medicine.medical_specialty
Very low-density lipoprotein Apolipoprotein B biology business.industry Cholesterol Mipomersen Familial hypercholesterolemia Lipoprotein(a) medicine.disease Gastroenterology Lomitapide chemistry.chemical_compound Endocrinology chemistry Internal medicine medicine biology.protein lipids (amino acids peptides and proteins) business Cardiology and Cardiovascular Medicine Lipoprotein |
| Zdroj: | Journal of the American College of Cardiology. 62(23):2178-2184 |
| ISSN: | 0735-1097 |
| DOI: | 10.1016/j.jacc.2013.07.081 |
| Popis: | Objectives This study sought to examine the efficacy and safety of mipomersen for reducing atherogenic lipids and lipoproteins in patients with hypercholesterolemia. Background Many patients on lipid-lowering therapies remain unable to achieve target low-density lipoprotein (LDL) cholesterol levels. Mipomersen, an antisense oligonucleotide inhibitor of apolipoprotein B, reduces LDL cholesterol and atherogenic lipoproteins. Methods This randomized, double-blind, multicenter study enrolled 158 patients with baseline LDL cholesterol levels ≥100 mg/dl with, or at high risk for, coronary heart disease who were receiving maximally tolerated lipid-lowering therapy. Patients received weekly subcutaneous mipomersen 200 mg (n = 105) or placebo (n = 52) for 26 weeks, with a 24-week follow-up period. Randomization was stratified by type 2 diabetes status. Results Sixty mipomersen and 44 placebo patients completed treatment. Mean baseline LDL cholesterol levels were 122.7 and 122.6 mg/dl in the placebo and mipomersen patients, respectively. Mipomersen reduced LDL cholesterol by −36.9% compared with placebo at −4.5% (p Conclusions Mipomersen significantly reduced LDL cholesterol, apolipoprotein B, and lipoprotein(a) in patients with hypercholesterolemia with, or at risk for, coronary heart disease not controlled by existing therapies. (Safety and Efficacy of Mipomersen [ISIS 301012] as Add-On Therapy in High Risk Hypercholesterolemic Patients; NCT00770146 ) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|